ARCUTIS BIOTHERAPEUTICS, INC.
ARQTCIK 0001787306 ยท Quarterly mode ยท latest period FY2025 (Q4) (ending 2025-12-31) ยท sourced from SEC EDGAR
At a glance ยท FY2025 (Q4)
Quality Score
Quality score
6-dimension fundamental snapshot ยท latest annual filed values ยท S&P 500 calibration
- Profitability0ROIC -3.4% (10% = solid, 20%+ = moat)
- Liquidity100Current Ratio 3.17 (above 1.5 = solid)
- Leverage71D/E 0.58 (under 0.5 = conservative)
- Efficiency57Asset Turnover 0.94x (1.0+ = capital-efficient)
- Growth100Revenue YoY +81.5% (10% = solid, 25%+ = elite)
- Margin Trend100Op Margin 8.6% ยท trend +88.9pts (4Q avg vs prior 4Q)
Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.
Capital allocation ยท trailing 4 quarters
how the company spent its cashBalance sheet ยท 2025-12-31
latest filed snapshotRecent performance ยท 28 quarters
Drill down
ARQT Sankey
See ARCUTIS BIOTHERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet โ every dollar accounted for, with prior-period comparison.
Open SankeyARQT Charts
28 quarters of historical line items โ Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open ChartsARQT Key Metrics
EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover โ 10 CFA-grade fundamentals derived from EDGAR data.
Open Key Metrics